about
Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults: A Systematic Review and Meta-analysis.Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.Pulmonary penetration of piperacillin and tazobactam in critically ill patients.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults.Population pharmacokinetics of teicoplanin in children.A rare case of shock.Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infectionsPharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimensPharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary AspergillosisPharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates.British Thoracic Society/Intensive Care Society Guideline for the ventilatory management of acute hypercapnic respiratory failure in adultsPharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa.Blood pleurodesis for the medical management of pneumothorax.Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days.Tissue penetration of antifungal agents.Posaconazole: the case for therapeutic drug monitoring.How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases.Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials.The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.Intratracheal Administration of Antimicrobial Agents in Mechanically Ventilated Adults: An International Survey on Delivery Practices and Safety.Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines.Estimate of the number of patients eligible for treatment with drotrecogin alfa (activated) based on differing international indications: post-hoc analysis of an inception cohort study in Australia and New Zealand.Aspergillus bronchitis without significant immunocompromise.Life-threatening pulmonary hypertension and right ventricular failure complicating calcium and phosphate replacement in the intensive care unit.Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers.The potential role of exhaled breath analysis in the diagnostic process of pneumonia - a systematic review.Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunction.Invasive pulmonary aspergillosis is associated with adverse clinical outcomes in critically ill patients receiving veno-venous extracorporeal membrane oxygenation.Peripheral neuropathy in patients on long-term triazole antifungal therapyA 27-Year-Old Woman With Acute, Severe Asthma Who Developed Respiratory FailureEffect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical TrialCardiorespiratory interactionImpact of a diagnostics-driven antifungal stewardship programme in a UK tertiary referral teaching hospitalAchieving high standards of training
P50
Q30235511-D9D00F2B-24AF-439E-8C28-385BE5956720Q33798203-380785A8-851E-4077-8972-0086DC079174Q34216623-42F8AB80-650F-43D2-AF4E-8D76B7DD2602Q34274190-EE64D32B-E042-4565-B534-559A3EEBD81FQ34518174-BD404FD0-F303-49F9-8239-9AEAA104CC51Q34596321-72F3EB42-C803-4184-A778-22BA97322927Q35552988-DDA22B5C-AE31-4EFF-89A5-705665DAEDCDQ35689202-5186E4F2-B1C7-44A2-A842-EB6D31BD6BD1Q36171570-2C07D369-A574-49C9-9B13-FB89AAED7D2CQ36171643-9222569E-FBAB-4BCB-AE00-46BF491789DEQ36276870-17C1CD1B-C8D3-41C2-B50D-E05960EA4A2DQ36439102-84226979-CAB0-4814-B4F5-1F3DDEF4779DQ36505301-73037516-CAEC-49DF-A29F-EEF8A4493608Q36684184-52D7EE88-5F6D-4A04-9FE4-1FC2F3886F39Q36707515-EDFE78C2-3C2C-46DF-9D1B-C8AA3F8DE40CQ36936353-7DD54A78-368B-45C8-B72A-ED36D90738EFQ37335725-63FA4C7F-82D4-4744-B3D5-3215B74AF2CEQ37404355-8B3CE00B-309A-43C2-85FE-C0FB7107C740Q37519843-B8EEFFCE-395D-45E0-8D37-38EC40EE43E2Q37544911-D92E4597-A94F-479C-8F07-340C409A53ECQ37973020-3B2FB985-C31C-4CBB-992A-404FE29E4CFEQ38225390-02C01775-FCA9-4C27-A72F-ABF5895E0011Q38730023-D257C691-1A7B-4CE6-A21F-C6FD99153717Q38741713-B93A371A-29BD-4B6C-9F96-C00D1F05AA00Q38837353-A45C004F-AA55-4CAA-B35F-144D0598DA54Q40762472-DFF3C505-3F3F-4D44-85A8-40017BE913A7Q40848111-BFC35010-930D-4F83-B64E-AD10050FE66FQ44403624-4E06E583-DB59-4705-83F5-A9C20A48A174Q46817409-793F2DE8-22E5-4648-A17A-973E5CE702D6Q46892181-7EF7D617-5E4D-45C2-AFC5-1E8878AEC135Q47642455-F5FD8962-E6A2-4638-A472-3F15A61C9944Q47667130-1E4AC3C0-78D0-47A2-922E-A76AE51440F3Q50873522-AC0482B8-1CBA-49C5-9B4D-05BC9804BB70Q54240772-135FDF34-ADC2-4FAB-8CE8-A60CADE8B2A3Q56837251-F4317428-FF53-4ABF-8751-005E6F1DC80CQ56837252-13F6F90A-4AFB-460A-A1E6-80767DC93B15Q57055898-BF6C28E7-1813-4425-90C7-232297566E51Q60705956-E6BE8928-23F7-44D6-93B9-1F4DE56DEDDFQ63304499-7382C43B-F2EC-43B0-B6E3-CF176D45BFE7Q82617791-1A5EAAC2-1C43-4886-BAFC-02F62384AD78
P50
description
researcher
@en
name
T W Felton
@en
T W Felton
@nl
type
label
T W Felton
@en
T W Felton
@nl
prefLabel
T W Felton
@en
T W Felton
@nl
P106
P31
P496
0000-0001-6868-6633